Veeva Systems Inc (VEEV): An IPO Loved by Hedge Funds

Initial Public Offerings (IPOs) can be an ideal way for investors to make a quick profit, especially if the company operates in a hot industry that garners a lot of market attention. For stocks that investors hold on to after their first day of trading, the opportunity could be even more interesting, as the shares potentially offer a fundamental growth story longer-term. We believe Veeva Systems Inc (NYSE:VEEV) could be one of those opportunities.

During the fourth quarter of 2013, many hedge funds bought new Class A shares of Veeva Systems, including Scott Fine and Peter Richards Empire Capital Management (who, with a 6% stake, is the sixth largest shareholder), Christopher Lord‘s Criterion Capital, Joe DiMenna‘s Zweig Dimenna Partners, and Brian Taylor‘s Pine River Capital Management.

Pine River Capital Management

Veeva Systems Inc (NYSE:VEEV) is a $4.4 billion market capitalization healthcare technology company that provides cloud-based software solutions to the biopharmaceutical (life sciences) industry for managing their content as well as relationships with customers and other external parties. Unlike larger peers salesforce.com, inc. (NYSE:CRM) or Oracle Corporation (NYSE:ORCL), Veeva is one of the early companies in the so-called Vertical Software-as-a-Service (SaaS) business, or providing cloud-based services tailored to the needs of specific, specialized markets, which some believe will be popular business models going forward. The company went public on October 16, 2013 by selling 15.0 million shares (including 3.3 million sold by existing owners) at an IPO price of $20, up significantly from an original range of $12-14 range. The stock closed that day at $37.16 and has been volatile, but is basically flat versus its first day’s closing price due to a combination of factors, including a high short interest (44% of float). Moreover, the company showed signs of slowing growth during its third quarter earnings release in early December (reporting year-over-year growth in revenue/billings was 95%/47%, versus 116%/75% in the prior quarter) and news of a lost high-profile client (Genentech).

Veeva Systems Inc (NYSE:VEEV)’s premium valuation reflects its high growth status, with a forward price / revenue and EV/EBITDA multiples of 17.7X (versus 3.6X for its peer group of healthcare technology companies) and 77.8X (versus 16.5X for peers), respectively. Interestingly, despite its growth, the company is profitable (a trait it had maintained even before going public, unlike other pre-IPO healthcare stocks), with margins much higher than the peer group median.

Longer-term, there will always be demand for Veeva Systems’s productivity and compliance solutions by the life sciences industry, which is under pressure to cut costs amid the expiration of patents on brand-name blockbuster drugs while navigating an increasingly complex and global regulatory environment. Hedge funds making a directional bet on the continuation of this secular industry trend could be gaining the appropriate exposure through Veeva Systems Inc (NYSE:VEEV), despite its lofty valuation.

Disclosure: none

Recommended Reading:

Ken Griffin and Citadel Are Bullish on Veeva Systems Inc (VEEV)

Empire Capital Management Adds Veeva Systems Inc (VEEV) to Its Equity Portfolio

Activist Investors are Betting on Allscripts Healthcare Solutions Inc. (MDRX)

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!